



1642

EXPRESS MAIL CERTIFICATE

251497205 US

Date 12/16/02 Label No. EU
I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post" Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

A. Stantini A. Stantini
Name (Print) Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No: 1225/1G584US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David BERD

Serial No.: 09/776,250

Art Unit: 1642

Confirmation No.: 8162

Filed: February 2, 2001

Examiner: Karen CANELLA

For: LOW DOSE HAPTENIZED TUMOR CELL AND TUMOR CELL EXTRACT
IMMUNOTHERAPY

RECEIVED

DEC 19 2002

TECH CENTER 1600/2900

MARKED-UP VERSION PURSUANT TO 37 C.F.R. 1.121

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

December 16, 2002

Sir:

13. (Amended) A method for inducing an anti-tumor response in a mammalian patient suffering from a tumor, which method comprises administering to the patient

a composition comprising a haptenized or non- haptenized tumor cell or tumor cell extract comprising from about 2×10^5 to about 2.5×10^6 tumor cells or cell equivalents per dose, without any adjuvant, wherein the tumor cells or cell equivalents are conjugated to a hapten, and rendered incapable of growth or multiplication in vivo, [The method of claim 10, wherein the composition is administered] prior to a second composition comprising an adjuvant and a tumor cell or tumor cell extract, which second composition [a) is conjugated to a hapten, and b)] contains (a) from about 2×10^5 to about 2.5×10^6 tumor cells or tumor cell equivalents, and (b) wherein the tumor cell or tumor cell extracts are conjugated to a hapten.

16. (Amended) The method of claim [13]15, wherein the composition is administered four to seven days prior to the administration of cyclophosphamide.

17. (Amended) The method of claim [10]13, wherein the tumor cells or tumor cell extracts originate from a tumor selected from the group consisting of melanoma, ovarian cancer, colon cancer, breast cancer, rectal cancer, lung cancer, kidney cancer, prostate cancer, and leukemia.

18. (Amended) The method of claim [10]13, wherein the tumor cells or tumor cell extracts are autologous.



9. (Amended) The method of claim [10] 13, wherein the tumor is melanoma.
20. (Amended) The method of claim [10] 13, wherein the patient is a human.

RECEIVED

DEC 19 2002

TECH CENTER 1600/2900